NASDAQ$INGN
Inogen Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Inogen's financial performance declined in Q2 2023 due to decrease in direct-to-consumer sales and international B2B sales, but the company is focused on improving profitability and expanding its portfolio.
Inogen reported a decrease in revenue by 19.1% to $83.6 million compared to the second quarter of 2022. The company experienced a GAAP net loss of $9.8 million and an adjusted EBITDA loss of $3.2 million. Inogen is focused on improving productivity, expanding its prescriber channel presence, and managing volatility in business-to-business channels.
- Total revenue decreased by 19.1% to $83.6 million, with currency fluctuations accounting for 0.6% of the decrease.
- GAAP net loss was $9.8 million, with an adjusted net loss of $5.8 million and an adjusted EBITDA loss of $3.2 million.
- Inogen entered into a share purchase agreement to acquire Physio-Assist, aiming to expand into the airway clearance market.
- The Inogen® Rove 6™ portable oxygen concentrator was introduced in the United States.
Headline financials
Revenue & EPS history
Inogen · Revenue · Quarterly
$83.6M
Forward guidance
Inogen now expects 2023 annual revenue of $315 million to $320 million and Adjusted EBITDA loss of $20 million to $25 million for the full year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
-0.7%
Avg return
Earnings day
-2.0%
Avg return
5 days after
-2.0%
Avg return
30 days after
49%
26 / 53 earnings
Positive
+35.5%
Q2 2024
Best reaction
-32.2%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.4% | -5.3% | -11.0% | |
| Q4 2025 | +4.3% | +5.8% | +6.0% | |
| Q3 2025 | -0.6% | +0.9% | -1.3% | |
| Q1 2025 | -11.5% | -14.4% | -8.1% | |
| Q4 2024 | -14.8% | -14.6% | -28.6% | |
| Q3 2024 | +15.9% | +9.1% | -0.7% | |
| Q2 2024 | +35.5% | +50.6% | +43.0% | |
| Q1 2024 | +14.6% | +17.7% | +17.7% | |
| Q4 2023 | -32.2% | -24.3% | -13.0% | |
| Q3 2023 | -1.3% | -8.1% | +10.0% | |
| Q2 2023 | -14.6% | -18.7% | -20.8% | |
| Q1 2023 | -6.1% | -19.3% | -21.9% | |
| Q4 2022 | -31.4% | -32.4% | -46.4% | |
| Q3 2022 | -12.5% | -10.0% | -0.8% | |
| Q2 2022 | -6.9% | -7.3% | -6.3% | |
| Q1 2022 | -2.2% | -7.8% | +2.0% | |
| Q4 2021 | +12.6% | +25.3% | +13.5% | |
| Q3 2021 | -6.0% | -7.3% | -21.6% | |
| Q2 2021 | -22.8% | -16.8% | -22.1% | |
| Q1 2021 | -3.5% | -2.4% | -12.8% | |
| Q4 2020 | +4.6% | +5.4% | -4.2% | |
| Q3 2020 | -7.1% | +9.8% | +33.0% | |
| Q2 2020 | +16.4% | +17.0% | -6.5% | |
| Q1 2020 | -21.4% | -20.1% | -24.2% | |
| Q4 2019 | +10.2% | +5.4% | +26.4% | |
| Q3 2019 | +17.3% | +19.7% | +24.4% | |
| Q2 2019 | -15.4% | -18.5% | -20.9% | |
| Q1 2019 | -28.8% | -22.2% | -31.8% | |
| Q4 2018 | -26.4% | -25.9% | -35.1% | |
| Q3 2018 | -18.8% | -22.6% | -24.8% | |
| Q2 2018 | +7.7% | +6.3% | +21.3% | |
| Q1 2018 | +21.0% | +18.7% | +26.7% | |
| Q4 2017 | -9.3% | -8.4% | -7.8% | |
| Q3 2017 | +16.1% | +12.9% | +15.0% | |
| Q2 2017 | -5.6% | -3.9% | +0.3% | |
| Q1 2017 | +0.2% | -2.6% | +11.9% | |
| Q4 2016 | +6.8% | +6.0% | +11.4% | |
| Q3 2016 | +13.0% | +15.8% | +22.3% | |
| Q2 2016 | +0.9% | +9.3% | +8.9% | |
| Q1 2016 | -6.6% | — | — | |
| Q4 2015 | +20.6% | — | — | |
| Q3 2015 | -1.8% | — | — | |
| Q2 2015 | +13.0% | — | — | |
| Q1 2015 | +4.9% | — | — | |
| Q4 2014 | +1.8% | — | — | |
| Q4 2012 | +1.8% | — | — | |
| Q3 2013 | -1.7% | — | — | |
| Q3 2014 | +6.0% | — | — | |
| Q2 2014 | +3.6% | — | — | |
| Q2 2013 | +3.6% | — | — | |
| Q1 2013 | +12.7% | — | — | |
| Q1 2014 | +12.7% | — | — | |
| Q4 2013 | -1.0% | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro